GSDMD and cancer: EVs expressing anti-HER2+ antibodies were used in a recent study to deliver GSDMD mRNA to HER2+ cancer cells in a HER2 overexpressing mouse model resulting in induced pyroptosis and a tumor immune response that significantly suppressed tumor growth and prolonged mouse survival compared to control mice that were treated with either PBS or unloaded EVs (Figure 7A-B) 121.